Effect of 5-alpha reductase inhibitors in animal models of Parkinson's disease.

Autor: Bourque M; Axe Neurosciences, Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada., Morissette M; Axe Neurosciences, Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada., Isenbrandt A; Axe Neurosciences, Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada; Faculty of Pharmacy, Laval University, Quebec, QC, Canada., Giatti S; Department of Pharmacological and Biomolecular Sciences, Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milan, Italy., Melcangi RC; Department of Pharmacological and Biomolecular Sciences, Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milan, Italy., Carta M; Department of Biomedical Sciences, 'Guy Everett Laboratory', University of Cagliari, Cittadella Universitaria SP 8, Monserrato 09042, Italy., Frau R; Department of Biomedical Sciences, 'Guy Everett Laboratory', University of Cagliari, Cittadella Universitaria SP 8, Monserrato 09042, Italy., Bortolato M; Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, 30 S 2000 E, Salt Lake City, UT 84112, USA., Soulet D; Axe Neurosciences, Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada; Faculty of Pharmacy, Laval University, Quebec, QC, Canada., Di Paolo T; Axe Neurosciences, Centre de recherche du CHU de Québec-Université Laval, Québec, QC, Canada; Faculty of Pharmacy, Laval University, Quebec, QC, Canada. Electronic address: therese.dipaolo@crchudequebec.ulaval.ca.
Jazyk: angličtina
Zdroj: Frontiers in neuroendocrinology [Front Neuroendocrinol] 2024 Oct; Vol. 75, pp. 101156. Date of Electronic Publication: 2024 Sep 29.
DOI: 10.1016/j.yfrne.2024.101156
Abstrakt: Parkinson's disease (PD) is characterized by motor symptoms due to loss of brain dopamine and non-motor symptoms, including gastrointestinal disorders. Although there is no cure for PD, symptomatic treatments are available. L-Dopa is the gold standard PD therapy, but most patients develop dyskinesias (LID), which are challenging to manage. Amantadine is recognized as the most effective drug for LID, but its adverse effects limit the use in patients. Here we review how 5α-reductase inhibitors (5ARIs), drugs used to treat benign prostatic hyperplasia and alopecia, exhibit beneficial effects in PD animal models. 5ARIs show neuroprotective properties in brain and gut dopaminergic systems, and reduce dyskinesias in rodent model of PD. Additionally, the 5ARI finasteride dampened dopaminergic-induced drug gambling in PD patients. Neuroprotection and antidyskinetic activities of 5ARIs in animal models of PD suggest their potential repurposing in men with PD to address gut dysfunction, protect brain DA and inhibit dyskinesias.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: